Rutgers University has launched a clinical trial to test the safety and efficacy of a new drug that could help prevent serious illness and death in early-stage COVID-19 patients. The drug is called EDP1815. It is administered orally, and is said to be anti-inflammatory and very safe. It will be given to newly hospitalized COVID-19 patients at Robert Wood Johnson University Hospital. They hope to determine if it can regulate the onslaught of something called “cytokine storms,” which cause the immune system to attack organs, such as the lungs, which lead to the immune system malfunctioning and become deadly – and is the reason for severe cases of respiratory distress and death. To read the full story.
- How can NJ cut high death rate among Black mothers in childbirth? This group has a plan
- Could polio be making comeback in Delaware Valley?
- Soaring Overdose Rates in the Pandemic Reflected Widening Racial Disparities
- Rutgers Will Conduct the Most Comprehensive Study Ever Done of High-Risk Children Newly Diagnosed With Type 1 Diabetes.
- A U.S.-Russia nuclear war could starve 5 billion to death, study says.